Methamphetamine self-administration in humans during d-amphetamine maintenance

Pike, Erika; Stoops, William W.; Glaser, Paul E.A.; Hays, Lon R.; Rush, Craig R.

doi:10.1016/j.drugalcdep.2014.02.497

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…d ‐Amphetamine treatment has failed to significantly decrease methamphetamine use in clinical trials . d ‐Amphetamine treatment also did not significantly attenuate methamphetamine self‐administration under a progressive‐ratio procedure in a single human laboratory study, although there was a trend for a decrease, and the d ‐amphetamine doses examined were small compared to the clinical trials. Consistent with these clinical trial and human laboratory results, a single preclinical study in nonhuman primates also reported that subchronic d ‐amphetamine treatment failed to decrease methamphetamine versus food choice at the group analysis level.…”

Section: Evaluation Of Candidate Medications In Preclinical Drug Versmentioning

confidence: 79%

Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder

Banks

2016

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Substance use disorders are diagnosed as a manifestation of inappropriate behavioral allocation towards abused drugs and away from other behaviors maintained by more adaptive nondrug reinforcers (e.g., work and social relationships). Substance use disorder treatment goals include not only decreasing drug-maintained behavior but also promoting behavioral reallocation toward these socially adaptive alternative reinforcers. Preclinical drug self-administration procedures that offer concurrent access to both drug and nondrug reinforcers provide a translationally relevant dependent measure of behavioral allocation that may be useful for candidate medication evaluation. In contrast to other abused drugs, such as heroin or cocaine, preclinical methamphetamine versus food choice procedures have been a more recent development. We hypothesize that preclinical to clinical translatability would be improved by the evaluation of repeated pharmacological treatment effects on methamphetamine self-administration under a methamphetamine versus food choice procedure. In support of this hypothesis, a literature review suggests strong concordance between preclinical pharmacological treatment effects on methamphetamine versus food choice in nonhuman primates and clinical medication treatment effects on methamphetamine self-administration in human laboratory studies or methamphetamine abuse metrics in clinical trials. In conclusion, this literature suggests preclinical methamphetamine versus food choice procedures may be useful in developing innovative pharmacotherapies for methamphetamine use disorder.

show abstract

Section: Evaluation Of Candidate Medications In Preclinical Drug Versmentioning

confidence: 79%

Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder

Banks

2016

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…One study examined D-amphetamine in managing methamphetamine use disorders and found a decrease, although not statistically significant, in self-administration of methamphetamine during Damphetamine maintenance therapy. 169 Further research is necessary to determine whether changes in stimulant dosage or route of administration are beneficial for treatment of amphetamine or methamphetamine SUDs in patients with ADHD.…”

Section: Cns Spectrumsmentioning

confidence: 99%

Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions

et al. 2020

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that manifests in childhood and can persist into adolescence and adulthood. Impairments associated with ADHD can impact quality of life, social interactions, and increase the risk of morbidity and mortality; however, for many patients, effective treatment can lessen these effects. Pharmacotherapy with stimulants or nonstimulants is recommended in conjunction with psychosocial therapy for most patients. Determining the optimal pharmacotherapy can be complex, and the clinician needs to consider many factors such as the patient’s age, comorbidities, and lifestyle. Furthermore, the needs of the patient with ADHD will change over time, with specific challenges to consider at each stage of life. A variety of Food and Drug Administration (FDA)-approved stimulant and nonstimulant formulations are available with different modes of delivery and durations of effect. This armamentarium of ADHD medications can be used to individualize ADHD treatment for each patient’s needs. This article combines current information from the literature and the first-hand experience of the authors to provide guidance on ADHD treatment options for patients of different ages and for some of the more common comorbidities.

show abstract

Methamphetamine self-administration in humans during d-amphetamine maintenance

Cited by 2 publications

References 20 publications

Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder

Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder

Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions

Contact Info

Product

Resources

About